Pages Menu

R&D

microscopeTrygg Pharma AS has two investigational drug candidates currently under development.

AKR-963

AKR-963 is a soft gel capsule investigational product containing highly concentrated omega-3-acid ethyl esters.
The product is being developed for use, subject to regulatory review and approval, as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia.
Trygg Pharma AS announced that the AKR-963 phase III study in the U.S. met its primary therapeutic endpoints in November 2011.  The data from that clinical trial and all other studies of AKR-963 are undergoing regulatory review.

AKR-996

AKR-996 is a soft gel capsule investigational product containing highly concentrated omega-3-acid ethyl esters.
The product is being developed for potential use as an adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g. statins, antiplatelet medicinal products, beta blockers, ACE inhibitors), and as a supplement to diet in endogenous hypertriglyceridemia when dietary measures alone are insufficient to produce an adequate response.